The anatomical distribution and organization of the peripheral nervous system as well as its frequent ability to reflect neurotoxic injury make it useful for the study of nerve fiber and ganglionic lesions. Contemporary neuropathologic techniques provide sections with excellent light-microscopic resolution for use in making such assessments. The histopathologist examining such peripheral nerve samples may see several patterns of neurotoxic injury. Most common are axonopathies, conditions in which axonal alterations are noted; these axonopathies often progress toward the Wallerian-like degeneration of affected fibers. These are usually more severe in distal regions of the neurite, and they affect both peripheral and central fibers. Examples of such distal axonopathies are organophosphorous ester-induced delayed neuropathy, hexacarbon neuropathy, and p-bromophenylacetylurea intoxication. These axonopathies may have varying pathologic features and sometimes have incompletely understood toxic mechanisms. In such neuropathies with fiber degeneration, peripheral nerve axons may regenerate, which can complicate pathologic interpretation of neurotoxicity. On occasion neurotoxins elicit more severe injury in proximal regions of the fiber (not included in this review). Axonal pathology is also a feature of the neuronopathies, toxic states in which the primary injuries are found in neuronal cell bodies. This is exemplified by pyridoxine neurotoxicity, where there is sublethal or lethal damage to larger cytons in the sensory ganglia, with failure of such neurons to maintain their axons. Lastly, one may encounter myelinopathies, conditions in which the toxic effect is on the myelin-forming cell or sheath. An example of this is tellurium intoxication, where demyelination noted in young animals is coincident with toxin-induced interference of cholesterol synthesis by Schwann cells. In this paper, the above-noted examples of toxic neuropathy are discussed, with emphasis on mechanistic and morphologic considerations.
INTRODUCTION
The basics of peripheral nerve structure and reaction to injury are considered elsewhere in this symposium, but a discussion of the utility of this tissue in the assessment of neurotoxicity and of the methods of tissue preparation for pathologic study is in order. The peripheral nervous system consists mainly of axons and their ensheathing cells and membranous coverings (myelin), populations of neuronal cell bodies arranged in ganglia, and a variety of supporting cells, connective tissue barriers, and vascular elements. The peripheral nervous system provides several advantages (relative to the central nervous system) for the toxicologic pathologist who needs to assess morphologic changes related to neurotoxicant exposure. As an example, peripheral nerve is readily accessible during necropsy dissections, and with a little extra care, it can be appropriately fixed to allow for critical histopathologic evaluation.
It is clear that not all neurotoxic conditions involve the peripheral nerve. Some, especially among the axonopathies and neuronopathies, may affect fibers in both the central and peripheral nervous systems, whereas others are restricted to one of these regions. For conditions affecting the peripheral nerve, the organization of this tis-sue is particularly useful in assessing proximodistal gradients of nerve fiber injury. In addition, morphometric studies are relatively simple in well-fixed tissue. The basic pathologic reactions are well defined in peripheral nerve and ganglia, and such events in this relatively simple (compared with brain or spinal cord) tissue are fairly easy to interpret. There is a potential for fiber regeneration in affected peripheral nerve, which may complicate these assessments in toxicologic studies. The major categories of neurotoxic peripheral nerve injury are neuronopathies, axonopathies, and myelinopathies, as discussed and exemplified below (Figure 1 ) (8) .
NEURONOPATHY Certain toxicants are specific for neurons and elicit primary injury in the cell body of these cells (Figure 1 ). This injury may be sublethal or lethal, depending upon the nature and degree of toxicant exposure and of the cellular susceptibility. Peripheral nerve is involved in these neuronopathies when affected cells either reside in peripheral ganglia or are in the brain or spinal cord and have axons that extend into peripheral nerve. In the case of toxic neuronopathies, these axons degenerate secondary to cell body injury at a rate that is consistent with the latter. Pyridoxine toxicity is chosen as an example of a neuronopathy that is manifest in the peripheral nervous system. FIGURE I.-Diagram of neuron that contributes to the peripheral nerve axonal population. Primary sites of toxicant-induced lesions are noted. Neuronopathic agents primarily involve neuronal cell bodies, but secondary axonal effects are seen as well. Toxicants inducing axonopathies elicit degeneration of the axon, whereas myelinopathic agents attack the Schwann cell/myelin sheath complex.
Pyridoxine Neurotoxicity
Vitamin B6 is a dietary requirement of nonruminant animals; the recommended oral daily dose is 2-4 mg in human adults. The vitamin has 3 naturally occurring forms-pyridoxol (pyridoxine), pyridoxal, and pyridoxamine-compounds in which alcohol, aldehyde, or amine groups are respectively located at the 4 position of the pyridine ring (24) . Of these, pyridoxine is the most commonly used as a supplement and therapeutic agent, and in megadoses, pyridoxine has been identified as a neurotoxicant. High doses, usually in the form of pyridoxine, have been used to treat such conditions as premenstrual or carpal tunnel syndromes. The nutrient has been similarly employed by bodybuilders. During the 1980s, attention was drawn to a neurologic disease found in people who were taking megadoses of vitamin B6 for prolonged periods of time. Thus, daily oral dosages of up to 6 g for 12-40 months led to progressive sensory neuropathy (manifested by sensory ataxia), diminished distal limb position and vibration sense, and paraesthesias and hyperesthesias (20, 97) . Significant reversal of these effects occurred following cessation of pyridoxine dosing. Therapeutic intravenous administration of doses exceeding 3 g/kg over a 3-day period elicited a more profound sensory neuropathy, with associated autonomic dysfunction in 2 adults (4). In these cases, the sensory deficits per-sisted despite cessation of dosing. The cellular target of this intoxication was the neurons of peripheral sensory ganglia, such as dorsal root (spinal) ganglia (97) .
These clinical observations were confirmed by a loworal dose pyridoxine (12-56.9 mg/kg/d) study in human volunteers (the authors of the paper) (9) . This demonstrated a dose-effect relationship in that lower doses required longer periods of administration in order to elicit a clinical effect. As examples, the 12-mg dosage required 7 months and the 56.9-mg dosage required 1.5 months to effect the onset of deficits such as altered sensation, gait abnormalities, and abnormal electrical expression of quantitative sensory thresholds. Interestingly, such sensory effects progressed for a period of weeks despite cessation of dosing and a return to normal of serum pyridoxal phosphate levels. Such clinical &dquo;coasting&dquo; was thought to be related to persistent metabolic defects in affected neurons. Animal experimental studies have expanded our understanding of pyridoxine (usually administered as pyridoxine hydrochloride) neurotoxicity, with 2 speciesdogs and rats-having primarily been employed. For canine studies, oral dosages of 50-300 mg/kg/d, for up to 112 days (47, 48, 60, 74, 95, 96) , were utilized. In rat studies, 3 intraperitoneal dosing regimens were generally employed, as follows: short term/high dose, 1,200 mg/ kg/d for 1-15 days (54, 62, 98, 112) ; intermediate dosing, 600 mg/kg/d for 1-15 days (59, 112) ; long term/low dose, 100-300 mg/kg/d for up to 12 weeks (62, 111, 112) . These experimental studies confirmed the susceptibility of neurons of peripheral sensory ganglia to large excesses in pyridoxine. This particularly affected large neurons with long processes, cells with the greatest metabolic susceptibility. A dose-response effect was seen. High and intermediate doses resulted in ataxia, with injury progressing to necrosis of the affected ganglionic neurons and associated sensory myelinated axonopathy and fiber degeneration. The latter was often distally accentuated in both peripheral and central (ie, spinal cord fasciculus gracilis and descending tract of trigeminal nerve) regions (54, 62) . Lower, more prolonged doses caused sublethal neuronal injury, with associated nerve fiber degeneration that was more profound distally (62) . Another pattern of evolution of pyridoxine-induced neuropathy was somatofugal axonal atrophy with modest axonal degeneration (112) . One study indicates that there is relatively uniform fiber degeneration along the entire length of the nerve with oral doses of 300 mg/kg for 8 or more days in dogs (60) .
The morphologic pattern of peripheral nervous system lesions of pyridoxine neurotoxicity thus reflects primary injury to the cytons of neurons residing in peripheral sensory (dorsal root, trigeminal) ganglia, with secondary degeneration of axons of affected cells. These cell body changes are manifest in cytoplasmic alterations such as vacuolization, increased dense bodies, neurofilament aggregates, and chromatolysis (Figure 2A, B ). More advanced neurotoxic changes led to neuronal death with phagocytosis by satellite cells ( Figure 2C ). Ultrastructurally affected neurons demonstrate cytoplasmic vacuoliza-FIGURE 2.-All sections are from rats intraperitoneally dosed with 1,200 mg/kg pyridoxine for 4 days, with a 2-day recovery period. A) Large neuronal cell bodies in trigeminal ganglion showing neurofilamentous cytoplasmic swelling (black arrow) and increased cytoplasmic dense bodies (white arrow). Toluidine blue and safranin stain (also used in D), X983. B) Excess neurofilaments distending trigeminal ganglionic neuronal cell body (similar to a cell in A), X7,342. C) Degenerating trigeminal ganglion neuron, X 12,923. D) Cross-sectioned sural nerve demonstrating varying stages of myelinated fiber degeneration, X 1,183. E) Cross-sectioned fiber in an advanced stage of Wallerian-like degeneration, manifested by axonal loss and the presence of myelin debris in a phagocytic Schwann cell. Vibrissal follicular branch of infraorbital nerve, X4,980. tion, loss of stacks of granular reticulum (chromatolysis), increases in lysosome-like dense bodies, masses of neurofilaments, abnormal (sometimes aggregated) mitochondria, and regions of granular degeneration of the cyton (Figure 2B , C). Studies suggest that cytoplasmic vacuolization of the neuronal cell, particularly in the region of the axon hillock and initial axonal segment, may be a primary lesion reflecting disruption of cell metabolism, with other changes that are attributable to the resulting deafferentation (59) .
The neuronal injury is also expressed in the myelinated fiber, with the patterns noted above. The changes are thus most advanced distally, and these changes reflect axonal injury secondary to the alteration of their ganglionic cytons (54, 62) . By light microscopy, such alterations included an increase in axoplasmic staining, including multifocal densities, and regions of axonal swelling and debris ( Figure 2D ). Affected fibers (axons and myelin sheaths) were degraded and phagocytized (by Schwann cells or macrophages); this represented an advanced stage of Wallerian-like degeneration ( Figure 2D , E). Later stages (approximately 40 days postdosing) had prominent bands of Bungner. These bands, representing columns of proliferated Schwann cells, are a necessary precursor for axonal regeneration. They sometimes contained single regenerating fibers, which were represented by naked axons or by thinly myelinated fibers. Surviving ganglionic neurons were histologically normal in later postdosing periods.
The neurotoxic mechanism of excess pyridoxine is not known, but several theories exist. The core structure of vitamin B6 is the pyrimidine ring (24), and the family of pyrimidines is known to have structurally dependent neurotoxic potential (93) . Pyridoxine is absorbed by unregulated passive diffusion in the gastrointestinal tract (92) , which leads to high circulating levels in the blood in megadosing states. This is thought to have a direct toxic effect on neurons, and the restriction of susceptible cells to peripheral ganglia is likely associated with the lower (&dquo;leaky&dquo;) blood-nerve barrier in such regions (84) . The presence of a more complete blood-brain barrier and of a saturable pyridoxine transport system in the brain and cord protects neurons in these regions from the high blood levels, in contrast to such cells in the peripheral nervous system (97). Rudman and Williams (92) advance a seemingly paradoxical theory, namely that the neurotoxic effect of megadoses of pyridoxine is elicited via deficiency of this vitamin. Deficiency of pyridoxine does elicit a neuropathy. Megadoses of pyridoxine may saturate hepatic pyridoxol kinase and pyridoxine phosphate oxidase, enzymes that convert the vitamin to the active form pyridoxine phosphate. This allows the inactive form, pyridoxine, to act as a competitive inhibitor to pyridoxol phosphate at the neuronal level. Other possible mechanisms include involvement of excess pyridoxine in local chelation of magnesium or the formation of quinone methide, which attacks polar and unsaturated groups (60) .
AXONOPATHY
In this category of neurotoxic injury, the primary expression is in the axon (Figure 1 ) (8) . Axon size appears to be a factor in that larger, longer myelinated fibers are more susceptible, and lesions are usually manifest in their more distal levels. The basic lesion is degeneration of the axon and, secondarily, of its myelin sheath. The neuronal cell body generally is intact, and thus, subsequent axonal regeneration is possible. The term dying-back neuropathy has been applied to these entities, which suggests that there is centripetal progression of injury from the synaptic ending. More recent studies indicate that the primary injury is usually distal but not terminal, with subsequent Wallerian-like degeneration distal to that site (13, 14) . As noted above, most toxic axonopathies occur distally, but on occasion, proximal examples, notably that caused by exposure to (3-(3'-iminodipropionitrile, do occur (8) . Examples of axonopathies chosen for more detailed discussion are those caused by the organophosphorous esters p-bromophenylacetylurea and 2,5-hexanedione.
Organophosphorous Ester-Induced Delayed Neuropathy
Organophosphorous (OP) compounds are widely employed as pesticides, lubricant additives, and plasticizers.
Members of this class of compounds have significant neurotoxic effects. One manifestation is an acute cholinergic toxicity based upon inhibition of acetylcholinesterase as a result of the phosphorylation of its active site. This acute neurotoxicity is not further considered here. It is a second OP-associated neurotoxic state that relates more to peripheral nerve (and central nervous system) pathology, namely OP compound-induced delayed neuropathy (OPIDN) (or neurotoxicity). Some workers have categorized the OP delayed neurotoxic conditions as Types I or II OPIDN (1, 3) . It is only Type I OPIDN that will be discussed and to which the OPIDN abbreviation will be applied. Although several experimental animal OPIDN models exist, this review is largely based on studies in domestic chickens (hens). The United States Environmental Protection Agency sanctioned this animal model for safety assessment (108) .
Several OP compounds elicit this neuropathy. These include protoxicants, such as leptophos and tri-ortho-cresyl phosphate (also known as tri-ortho-tolyl phosphate), and direct toxicants, such as cyclic tolyl saligenin phosphate (the active metabolite of tri-ortho-cresyl phosphate), mipafox, diisopropyl phosphorofluoridate (DFP), and di-n-dibutyl-2,2,-dichlorovinyl phosphate (28). The structural features of OP delayed neurotoxicants include the following (28): 1) the phosphorus must be in a pentavalent state; 2) the atom with the coordinate covalent bond attached to the phosphorus must be an oxygenprotoxicants with sulfur attached by a coordinate covalent bond can be oxidized to active neurotoxicants; and 3) there must be at least 1 oxygen or amine bridge linking an R group to phosphorus.
Neurotoxic OP compounds can inhibit esterases by phosphorylation of the active site of the enzymes. There is an association between inhibition of the nervous system enzyme neuropathy target esterase (NTE) and subsequent development of OPIDN (51) . NTE is a carboxylesterase found in the smooth endoplasmic reticulum of cells in the nervous system and other tissues (27). The sequence of reactions between the delayed OP toxicants and the active site of NTE leads to stable inhibition of the enzyme in a fashion and intensity associated with subsequent neuropathy (51, 52) . The toxicants form a Michaelis complex with NTE, with loss of their acidic groups and phosphorylation of the enzyme's active site.
This results in reversible NTE inhibition, which must be followed by a process termed aging of the phosphorylated enzyme if OPIDN is to occur. Aging is an intramolecular rearrangement resulting in a negatively charged phosphoryl residue attached to the phosphorus, which essentially irreversibly inhibits the activity of the esterase (27, 52) .
There is good correlation between temporal and quantitative patterns of NTE inhibition and subsequent development of OPIDN. Inhibition and aging of at least 70% of brain or spinal cord NTE within 48 hours of a single neurotoxic dose is likely to be followed by OPIDN in 7-10 days (51, 52) . However, a dose-related effect on NTE inhibition/neuropathy has been noted (29). For studies using smaller multiple dosages, a threshold of 45-65% inhibition of NTE appears to be necessary before OPIDN develops (27).
Although the above-noted association of NTE inhibition/aging and development of neuropathy is well defined, it is not clear what role the enzyme inhibition plays in the pathogenesis (27, 69, 71, 89) . There are examples of divergence of NTE inhibition and neuropathy development, as when OP-induced inhibition of the enzyme is seen in animals, such as young chicks, quail, rats, or mice, that do not readily manifest OPIDN (26, 36, 85, 109, 110) . In addition, although NTE is rapidly inhibited by OP delayed neurotoxicants, it may no longer be inhibited when clinical and pathologic manifestations of the neuropathy are subsequently expressed (27, 28) .
Neuropathologic studies of experimental OPIDN induced by pentavalent phosphorus compounds (Type 1 OPIDN) have revealed a consistent pattern of lesions, which is felt to represent the morphologic substrate of the entity (56, 61, 88, 104) . The primary lesion is a bilateral axonopathy involving distal levels of axons and their terminals, primarily affecting larger/longer myelinated central and peripheral nerve fibers, leading to breakdown of affected neuritic segments and, secondarily, to breakdown of their myelin sheaths. These lesions generally begin to develop at or near the end of the postdosing symptom-free period. In experimental studies with chickens, this distal pattern of injury is manifested by clinical neuropathy, which is associated in the central nervous system with bilateral long-tract involvement, such as in cervical spinal cord, medullary and cerebellar levels of the ascending spinocerebellar tracts and fasciculus gracilis, and lumbar levels of the descending medial pontine spinal tracts (17, 19, 56, 103, 104) .
Pertinent to this discussion are peripheral nerve lesions in distal regions of long myelinated fibers in chickens, particularly in the legs (17, 25, 26, 32-34, 53, 56) . Attention has been directed to the sensitivity of the nerve supplying the biventer cervicis muscle and the large-diameter myelinated fibers of the tibial nerve branch to the lateral head of the gastrocnemius muscle in the hen (25, 34, 61) .
By light microscopy, these lesions were seen to consist of axonal swelling with attenuated myelin sheaths ( Figure  3A ). The swollen axons were pale staining or debris-laden and dark staining ( Figure 3A ). These lesions increased in affected regions as the clinical neuropathy advanced. Later lesions included fragmentation of affected fiber segments as the process of Wallerian-like degeneration ensued ( Figure 3B , C). This was associated with formation of myelin-rich ovoids and phagocytosis of the degraded elements by macrophages or Schwann cells ( Figure 3D ).
Ultrastructurally, proliferation of intra-axonal tubules and cisterns, which resembled smooth endoplasmic reticulum, and vesicles were early morphologic events in OP-IDN (10, 11, 13, 14, 17, 88) . Other early changes, seen in cats dosed with DFP, were peripheral myelinated fiber distal, nonterminal varicosities that were attributable to the presence of abnormal membrane-lined vacuoles in axons, inner myelin sheaths, or both (which preceded fiber degeneration) (13, 14) . Researchers suggest that such vacuolar alterations represent a &dquo;chemical transection&dquo; of the fiber, which leads to its subsequent breakdown.
Following these early ultrastructural events, there is axonal swelling, with secondary attenuation of the myelin sheath. Electron-microscopic study revealed that numbers of these swollen axons contained disorganized masses of normal and altered mitochondria, cytoskeletal components (neurofilaments), lysosome-like dense bodies, and generation. With advanced breakdown of the fiber in OP-IDN, proliferation of Schwann cells within their basal lamina forms the band of Bungner. The latter is a site of subsequent nerve fiber regeneration, which is robust in OPIDN following a single dose of the toxicant (57). Con-sistent with other forms of nerve fiber degeneration, there is a failure of such regeneration in the central nervous system in OPIDN (57) .
Although human cases of OPIDN have been recognized for over a century and although a major outbreak occurred in the 1930s, the pathogenesis of the neuropathy is still not fully understood. Clearly, sublethal injury occurs in neurons bearing the susceptible long axons in the asymptomatic postdosing period, which in turn leads to fiber degeneration.
Experimental studies have proposed possible pathogenetic pathways. As noted earlier, there is an association between NTE inhibition and subsequent OPIDN, although the precise mechanistic role of this relationship is unknown. There does appear to be a toxicant-associated increase in Ca2+ calmodulindependent protein kinasemediated phosphorylation of out-and j3-tubulin, a microtubule-associated protein (MAP-2), and neurofilament triplet proteins in affected nervous tissue (2, 65) . The proposed mechanism is that intra-axonal Ca2+ is thought to induce conformational and activity changes in the kinase that lead to cytoskeletal hyperphosphorylation, which contributes to the axonal degeneration.
A role for increased Ca2+ in affected axons has been suggested by El-Fawal et al (30, 31, 33) . These investigators noted an increase in calcium-activated neutral proteases (calpain) in sciatic nerve and brain of hens dosed with tri-ortho-cresyl phosphate or phenyl saligenin phosphate, which was temporally associated with clinical and morphologic expression of the neuropathy. In addition, pretreatment with calcium channel blockers protected toxicant-dosed hens from the full expression of the neuropathy. Other suggested pathogenetic mechanisms include alterations in axonal transport, such as decreased retrograde transport or biphasic alteration of slow anterograde transport (44, 76) .
The expression of OPIDN in hens can be modified by the sequence of administration of reversible NTE inhibitors (nonneurotoxic), such as phenylmethylsulfonyl fluoride, and neuropathy-inducing OP compounds (70, 86) . Dosing with the reversible inhibitor prior to the delayed neurotoxicant inhibits development of OPIDN, presumably by tying up the active site on NTE. This is termed protection. Reversing the sequence gives promotion (potentiation), at which point the expression of OPIDN is enhanced. This occurs when the reversible inhibitor exacerbates the OP delayed neurotoxicant's effect by some unknown mechanism. Because NTE can be maximally inhibited by the first (neurotoxic) OP compound, the enhancement by the second (reversible) NTE inhibitor suggests that the enzyme is an unlikely target for promotion (71, 87) .
p-Bromophenylacetylurea
As the name implies, p-bromophenylacetylurea (BPAU) is a phenylacetylurea compound with bromide at the para position of the phenyl ring (78, 79) . This compound is a neurotoxicant that produces a progressive central-peripheral distal axonopathy that affects both sensory and motor myelinated fibers (49, 78, 81) . There is a delay in the onset of clinical signs of about 1 week following treatment of animals with neurotoxic dosages of this compound (49, 55) . The mechanism of neurotoxicity is related to the complex effects that BPAU has on fast axonal transport, which is initiated during this preclinical period. Specific alterations leading to this neu-ropathy include toxicant-induced accelerated processing of proteins in the neuronal Golgi apparatus, with associated premature onset of anterograde fast axonal transport and reduction of axonally delivered protein (79, 83) . Protein that undergoes this abnormal Golgi processing is thought to have alterations that may lead to inefficient switching at the anterograde/retrograde axonal transport turnaround in the distal level of the axon, with associated reduction in the amount of recycled protein (79, 82, 83) . In some fashion, these alterations are thought to lead to sporadic local stasis of the fast-transported proteins, with associated intra-axonal tubulomembranous accumulations that are an ultrastructural feature of the neuropathy (82) .
Studies have shown that the rat is the experimental animal of choice, and the single intraperitoneal neurotoxic dose is in the 200-400 mg/kg range. In this model, neurological signs are noted at about 1 week postdosing, and these signs include hind-leg ataxia and weakness, which progresses to paralysis over the next 2 weeks (49, 50, 55, 81, 83) . Some studies have used 2 or more doses by either the intraperitoneal or oral (gavage) route without a significant change in the clinical picture (12, 78, 79) . More detailed clinical evaluation using the functional observational battery assessment of neurologic status demonstrated a range of clinical deficits including decreases in activity, ability to remain on a rotorod, rearand forelimb grip strength, and responses to stimuli (55) . One striking feature of BPAU intoxication in rats is a weight loss of some 5-10%, which occurs rapidly after a single exposure to the toxicant and which is maintained for at least 4 weeks (50).
Associated with the neurologic signs is a progressive distal axonopathy that affects longer sensory and motor fibers in both the central and peripheral regions of the nervous system (78, 81) . Such lesions were initially and most prominently noted in distal fiber regions (as in rostral levels of long ascending central tracts like the spinocerebellar and fasciculus gracilis or distal peripheral nerve levels like the peroneal, tibial, sural, and trigeminal vibrissal follicular branch) (12, 55, 81) . The distal neuropathic process also affects axon terminals (12, 50) . By light microscopy, the affected peripheral nerve myelinated axons had intra-axonal densities and changes in staining, and they were often either swollen or collapsed ( Figure 4A ). Swollen axons were often marked by aggregation of the synaptic vesicle membrane component synaptophysin (55) . Such accumulation of this neuronal perikaryal synthesized protein is considered secondary to interruption of axonal transport as a result of distal Wallerian-like degeneration. As the degradative process ensued, there was breakdown and phagocytosis of both the axon and its myelin sheath, which thus formed myelin ovoids that were characteristic of Wallerian-like degeneration ( Figure 4B ). Endoneural edema was often present in severe lesions ( Figure 4A ). In the period following clinical onset, there was an increase in the severity of the neuropathy, and lesions were noted in more proximal regions of the nerve (55) . Similar degradative changes were also seen in the spinal cord and brain stem. By transmission electron microscopy, the affected axons had granular degeneration of axoplasm and its organelles and an in-FIGURE 4.-A) Varying stages of myelinated fiber degeneration (arrows) are seen in the cross-sectioned sciatic nerve of a rat 14 days after a neurotoxic dose of p-bromophenylacetylurea (BPAU). Endoneural edema is manifested by increased separation of myelinated fibers. Toluidine blue and safranin stain, X320. B) Cross-sectioned tibial nerve branch in a rat 14 days after a neurotoxic dose of BPAU. Profiles of myelin-rich ovoids characteristic of Wallerian-like degeneration are noted (arrows). Toluidine blue and safranin stain, X 1,275. C) Granular degeneration of a crosssectioned myelinated axon in the sciatic nerve of a rat dosed as in figure A, X 39,928. crease in tubulomembranous or vesicular networks (Figure 4C) (82) . One feature of spinal cord axons was the presence of dystrophic changes, which were manifested as hyalin swelling of affected neurites as a result of intraaxonal accumulations of mitochondria, electron-dense granules, and a prominent varicose anastomosing tubular vesicular system (12) . The latter fibers were thought to be related to frustrated attempts at regeneration in the central nervous system tracts, which comprise an environment that was not supporting such a process.
Hexacarbon Neuropathy
Hexacarbon neuropathy was detected in the 1960s and 1970s in workers involved in laminating or in shoe or furniture manufacturing as well as in individuals who were deliberately inhaling vapors from solvents and glues (99, 102) . In the industrial settings, there was exposure for months to the solvent n-hexane (by respiratory or dermal routes), with ambient air concentrations as high as 2,500 ppm. Affected individuals developed distal, bilateral, progressive sensorimotor neuropathy, and nerve biopsies revealed myelinated axonal paranodal neurofilament-rich swellings and distal axonal degeneration (90) .
Regression of clinical deficits was often seen months af-
ter cessation of exposure.
The human experience was reproduced in rats and other experimental animals. In rats, the clinical effects of the neuropathy, such as weakness that was greater in the hind limb than in the forelimb, and ataxia were the clinical representation of the central-peripheral distal axonopathy that was noted in pathologic studies (100, 101) . As this classification implies, both the peripheral (described below) and central nervous system fibers are affected in this y-diketone toxicity. Using 2,5-hexanedione as the prototypic toxicant, lesions are most prominent in distal, although not necessarily terminal, levels of affected neurites. With subacute or subchronic dosing paradigms, several neuropathologic features are noted, and as indicated below, their clinical relevance is a matter of some debate (5, 22, 66, 68) . Classical descriptions of the experimental neuropathy focused on the presence of axonal accumulations of disordered arrays of 10-nm neurofilaments, which led to marked distention of the neurite (Figure 5A , B) (100-102). The term giant axonal swelling has been applied to this lesion. The neurofilamentous aggregates were initially noted at proximal paranodes (the portion of the axon just proximal to the narrowing of the node of Ranvier). In association with these swellings, there was thinning of the overlying myelin sheath, which led to paranodal demyelination ( Figure 5A, B ). This may have been related to slippage of the sheath secondary to the axonal enlargement. Later in the course of treatment, the more proximal and intemodal regions of axons also showed these swellings. In addition, there may be Wallerian-like degeneration of the fiber distal to the site of swelling. Cessation of dosing leads to diminution of the swellings along with regeneration of the degraded distal fiber levels. In long-term exposures, neurofilamentous swellings have also been noted in some unmyelinated axons.
Another myelinated fiber lesion that has engendered recent interest is axonal atrophy, a change that had been previously noted in hexacarbon-treated rats (72, 73, 80, 91) and in vitro neuronal preparations (77) . Recent studies by Lehning and colleagues (66) demonstrated that subacute intraperitoneal or subchronic oral (drinking water) administration of 2,5-hexanedione led to equivalent clinical hind-limb weakness, despite the difference in the duration of compound dosing. That is, clinical signs classified as &dquo;moderate&dquo; took 86 days and signs classified as &dquo;severe&dquo; took 103 days with oral administration, whereas intraperitoneally dosed animals reached the moderate stage at 32 days (20 toxicant administrations). By either route, axonal atrophy (with less circular cross-sectional profiles) at an intensity that correlated with clinical deficits was a major pathologic feature (Figure 5C, D) . The hexacarbon-induced atrophy initially developed distally and later extended to more proximal levels of peripheral nerve (35, 67) . Neurofilamentous axonal swellings were also noted in the orally (subchronic) dosed rats, more at distal levels, but these were both rare and truncated in peripheral nerves of the intraperitoneally (subacute) dosed rats. In an oral dose-effect study of 2,5-hexanedione in rats, it was demonstrated that the presence of axonal swellings correlated inversely with the dose rate but directly with the length of exposure (67) . In contrast, the atrophy was progressive with all doses, was initiated distally, extended proximally during the course of treatment, and was associated with diminished neurofilament content of affected nerves ( Figure 5D ) (18, 67) . This body of work suggests that axonal atrophy occurs independently of the neurofilamentous swellings and may represent an important lesion of hexacarbon neuropathy.
For pathogenetic studies, a major breakthrough was the determination that 2,5-hexanedione, the y-diketone metabolite of n-hexane and methyl-n-butyl ketone, was the ultimate toxin in hexacarbon neuropathy (58) . As noted above, the nature of the clinically relevant toxicant-induced lesion and of its pathogenesis has been somewhat controversial. An elaborate series of studies led to the conclusion that the y-diketone interacted with lysine Eamino groups on neuronal neurofilaments to produce a pyrrole. This interaction led to the formation of axonal neurofilamentous swellings in more distal regions of central and peripheral nervous systems, an event that was felt to be the major effect of the y-diketones (5-7, 37, 94) . There was later, associated degeneration of yet more distal peripheral fiber levels. Several mechanisms to explain how this pyrrole formation produced these neurofilamentous swellings have been proposed. In one scenario, the y-diketone-induced process alters the physicochemical properties of these proteins by converting hydrophilic charged -NH3+ groups to hydrophobic neutral pyrrole groups. The latter were thought to disrupt the cytoskeletal supramolecular structure, thus promoting neurofilament aggregation, possibly by decreasing the &dquo;solubility&dquo; of the filaments (21, 23, 94, 113) .
A second approach holds that the initial 2,5-hexanedione-induced pyrrole formation is followed by conversion to an electrophile, with subsequent attack on protein nucleophiles, leading to covalent intraand intermolecular neurofilament cross-links and cytoskeletal disruption FIGURE 5.-All photographs are cross sections of indicated nerves from rats dosed daily (by gavage) with 250 mg/kg of 2,5-hexanedione for 69 days. A) Two sciatic nerve fibers have giant axonal swelling, with relatively thin myelin sheaths (arrows). Some atrophy of adjacent fibers is noted. Toluidine blue and safranin stain, X 1,017. B) The ultrastructural appearance of a tibial nerve fiber with its axon distended by masses of maloriented neurofilaments (giant axonal swelling), X9,502. C) Many atrophic, misshapen tibial nerve myelinated fibers are noted (arrows). Toluidine blue and safranin stain, X 1,363. D) Ultrastructural appearance of cross-sectioned tibial nerve atrophic myelinated axon. Inset shows reduction of axonal neurofilaments and approximation of microtubules (arrows), X 12,407; inset, X 87,000. (6, 7, 38, 43, 91) . This is manifested by progressive proximodistal derivatization that promotes neurofilament accumulation and associated distal axonal swellings, initially noted at proximal heminodes, where the narrowing of the nodal constriction impedes the movement of the cross-linked neurofilaments (41, 42) . Later in the course of the neuropathy, there is involvement of intemodal regions of the axon. Administration of more potent hexacarbon pyrrole inducers, such as 3,4-dimethyl-2,5-hexanedione, leads to more proximal deposition of axonal swellings (6, 7, 41 ) . The basis by which the neurofilament serves as the primary toxic target is thought to rest on the relative stability of these fibrils and their slow transport down the axon from the perikaryal site of synthesis. This allows the derivatization and cross-linking noted above.
While there has been much attention paid to the neurofilament-rich giant axonal swellings as the primary neurotoxic change in hexacarbon neuropathy, as noted above, recent studies have suggested that axonal atrophy in rats may instead represent the most clinically relevant lesion (66) . This conclusion was based upon the above-described studies, which demonstrated that a reduction in myelinated axonal caliber was progressive with 2,5-hexanedione multiexposure studies using either intraperitoneal (17-32 days of administration) or oral (77-103 days) dosing routes. Although the mechanism by which the ydiketone elicits axonal atrophy is not fully understood, selective acceleration of neurofilament transport has been suggested as an element in one model of the neuropathy (72) .
MYELINOPATHY
The preceding sections have dealt with injury to neuronal elements of peripheral nerve. Some toxicants primarily target supporting or glial elements of peripheral nerve, most prominently the Schwann cells and the myelin sheaths produced by a subpopulation of them ( Figure  1 ). Prior to a consideration of a specific Schwann cell/ myelin injury-based neuropathy, a brief overview of these cells is presented (75) . Schwann cells are normally restricted to peripheral nerve and ganglia and have 2 major phenotypes; they are either myelin or non-myelinforming. For the former, each Schwann cell ensheaths and myelinates a segment of an axon between consecutive nodes of Ranvier (hence, an intemodal segment of myelin). This involves larger (vs smaller) axons. In doing this, the myelinating Schwann cells develop the capacity to synthesize large amounts of protein (such as Po, myelin basic protein, myelin associated protein) and lipids (cholesterol, phospholipids, galactolipids [cerebrosides and sulfatides]) and to form these into the periaxonal concentrically wound, compacted, complex multilamellar myelin sheath. During development, these processes must be performed in a relatively short, tightly programmed interval, during which they make considerable metabolic demand on the involved glia.
Another population of Schwann cells segmentally envelops smaller (0.1-2 ~Lm in diameter, usually several [ 1-100 range] per Schwann cell) axons but does not generate myelin. Both these nonmyelinating and myelinating Schwann cells evolve from common precursor cells. The latter are marked by the expression of nerve growth-factor receptor and glial fibrillary acidic protein. In the Schwann cells that commit to myelination, these are lost, while synthesis of myelin components is upregulated. This closely integrated system of peripheral nerve myelin and/or myelin-forming cells is targeted by a number of toxicants, most notably hexachlorophene, lead, and the example chosen for discussion, tellurium (8) . Tellurium Neuropathy Tellurium elicits injury to Schwann cells and, secondarily, to the peripheral nerve myelin sheaths formed by these cells in a prototypic fashion. A well-studied animal model is used, in which weanling rats (<25 days of age) are fed a diet containing 1-1.5% elemental tellurium by weight (15, 63) . These rats are still actively growing and have a transient sensitivity of their myelinating Schwann cells to this dietary tellurium exposure. Clinically this is expressed by hind-limb paresis, which begins at about 3 days of dietary exposure and which progresses to day 7. The bases of this clinical condition are complex neuropathic events involving peripheral nerves and, in particular, the Schwann cells that form larger myelin intemodes (16) . Affected Schwann cells develop cytoplasmic lipid droplets and membranous whorls, which progressively increase in severity and in number of affected cells from 2 to 7 days on the tellurium-containing diet ( Figure 6A ) (40, 45, 46, 63) . These cytologic changes in myelinating Schwann cells are associated with demyelination, which progresses to loss of the entire intemodal segments, when fully expressed. Affected myelin unravels 1-2 days after Schwann cell injury, with splitting of the intraperiod and major dense lines, vesicular transformation, and removal of debris by Schwann cells (Figure 6B , C) (64, 75) . There is little associated axonal degeneration. Nonmyelinating Schwann cells and central nervous system myelin and oligodendrocytes are unaffected.
Other pathologic events in peripheral nerves of tellurium-treated rats include breakdown of blood-nerve barrier (endoneurial edema) and infiltration of macrophages (15, 75) . The approximate times for the appearance of the neurotoxic events following initiation of tellurium exposure in this animal model are as follows: inhibition of cholesterol synthesis, 12 hours, see below (15, 75) .
The morphological and clinical events noted above reflect the toxic effects of tellurium on the susceptible (larger) Schwann cells. Although elemental tellurium is administered in the diet and absorbed in the intestine, methylation in the liver produces dimethyltelluronium chloride, considered to be the major circulating neurotoxic species (39) . It is theorized that this compound is metabolized to the most active inhibitor of squalene epoxidase (see below), the tellurite ion (Te03=), in target Schwann cells (39, 75) .
The primary effect of tellurium on susceptible Schwann cells is diminished cholesterol synthesis as a result of toxicant-related inhibition of the obligate enzyme in this biosynthetic pathway, squalene epoxidase (75, 105, 106) . As a consequence, there is an excess accumulation of the substrate squalene. The diminished cholesterol (a major myelin lipid) not only halts ongoing myelination but also destabilizes myelin that has already formed, leading to the demyelination of larger intemodes (75, 106) . The administration of tellurium in this model occurs during a period of rapid myelin accumulation, when the demand for Schwann cell cholesterol synthesis is maximal, especially in cells supporting larger internodes : hence, the susceptibility of such Schwann cell/ FIGURE 6.-Cross sections of sciatic nerve of weanling rats fed a diet with 1.25% elemental tellurium (tissue specimens provided by Dr Jeffrey Goodrum, University of North Carolina, Chapel Hill). A) Early changes of intracytoplasmic lipid droplet and membranous inclusions (arrow) are seen in a Schwann cell from a rat that had been on the diet for 5 days. Note that the myelin sheath (arrowhead) is intact, x 16,515. B, C) Active demyelination characterized by splits and separations with myelin sheath is seen at the light (B, arrows) and transmission electron-microscopic (C) levels in a rat that had been on the diet for 5 days. Endoneural edema manifested by increased separation of nerve fibers is seen (B). B) Toluidine blue and safranin stain, x 1,860. C) X 13,125. D) Thinly myelinated fibers (arrows) indicative of remyelination are seen at 9 days on the diet.
Toluidine blue and safranin stain, X 1,860. myelin units (75) . In other sites of cholesterol synthesis, such as the liver, the inhibition of squalene epoxidase is circumvented by use of alternative pathways, a condition not found in Schwann cells (75) .
The tellurium-induced demyelination is associated with altered gene expression in Schwann cells. This includes downregulation of mRNA expression for myelin proteins such as Po and enzymes involved in myelin lipid formation (105) . The latter include 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol synthesis, and uridine diphosphate galactose :ceramide galactosyltransferase (involved in biosynthesis of &dquo;myelin-specific&dquo; galactocerebroside) (75, 106) . In addition, nerve growth-factor receptor mRNA is upregulated (105) . This demyelinating effect of dietary tellurium is transient, presumably relating to a temporal period of susceptibility of Schwann cells during growth. Even in rats maintained on the tellurium-containing diet, and more so when the latter is removed at 7 days, remyelination of affected fibers and clinical improvement are seen ( Figure  6D ) (8, 16, 75) . In the case of remyelination, several Schwann cells produce myelin to occupy the internode once formed by a single one of these glia. This results in shorter and thinner internodes. Underlying this response is reversal of the metabolic events characterizing the demyelination noted above (46, 107) .
SELECTED ASPECTS OF FIXATION AND PROCESSING OF PERIPHERAL NERVE FOR PATHOLOGIC STUDY
What follows are some brief comments relating to fixation and embedding of peripheral nerve tissue for histopathologic study. The basic principal of such fixation is that it be rapid and adequate and that distortions of nerve length and compression be avoided. The peripheral nerve needs to be fixed in an elongated (but not excessively stretched) state. Perfusion fixation is preferred, but methods using in situ preservation (initiating the process by dripping fixative on the exposed nerve prior to its removal at necropsy) have been used. These may not be feasible when high-volume animal sacrifice and necropsy for large toxicity studies are undertaken. An acceptable alternative is to remove the indicated length of fresh peripheral nerve at necropsy, gently adhere it to an index card in an elongated state, and immerse the cardboard and adherent nerve in the fixative. This allows fixation of straight segments of nerve.
Immersion fixatives can vary depending on whether histopathology is to be supplemented by ancillary studies, such as immunohistochemistry or electron microscopy. For the latter, buffered glutaraldehyde solutions of about 2.5% are useful. A variety of fixatives, usually paraformaldehyde based, or even 10% neutral-buffered formalin are employed for immunohistochemistry, and the former can also be used for electron microscopy. Any of the above can be used for light microscopy of epoxy resinembedded tissues. For the latter, after fixation, the ends of the nerve segment that were handled in the fresh state are trimmed away. The tissue is then postfixed in osmium tetroxide, embedded in epoxy resin, and sectioned at about 1 J.1m thickness and stained. These methods provide light-microscopic sections with optimal resolution, which form the basis of contemporary peripheral nerve histopathology. Appropriately fixed tissue embedded in these resins also provides samples for transmission electron microscopy, but these samples are not suitable for immunohistochemistry. Other embedding media, such as paraffin, are better suited to immunohistochemistry. nedione and perdeuterio-2,5-hexanedione in the rat. Toxicol Appl 
